Business Context and Reporting Period
This Form 8-K was filed by DaVita Inc. on March 12, 2018. The report addresses a regulatory development concerning the pending sale of DaVita Medical Group to Collaborative Care Holdings, LLC (a subsidiary of Optum, Inc.), pursuant to an Equity Purchase Agreement dated December 5, 2017.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to DaVita's Annual Report on Form 10-K for the year ended December 31, 2017, for financial data.
Material Changes and Events
- FTC Second Request: On March 12, 2018, DaVita received a "second request" for additional information and documentary material from the U.S. Federal Trade Commission (FTC) under the Hart-Scott-Rodino Antitrust Improvements Act.
- Waiting Period Extension: The second request extends the statutory waiting period for the transaction until 30 days after DaVita and the Buyer substantially comply with the request, unless the period is extended voluntarily or terminated sooner by the FTC.
- Transaction Status: The completion of the sale of DaVita Medical Group remains subject to regulatory approvals and customary closing conditions.
Guidance, Outlook, and Risks
Outlook: DaVita continues to expect that the Pending Transaction will close in 2018. The company states it is working diligently and cooperatively with the FTC.
Risks and Contingencies: The filing highlights several risks associated with the transaction, including:
- Uncertainty regarding the timing and receipt of regulatory approvals.
- Potential operational disruptions affecting business relationships.
- Uncertainties related to the use of proceeds, including the ability to repurchase stock.
- General risks detailed in the company's Form 10-K.
Key Facts for Investor Verification
- Verify the timeline for compliance with the FTC's second request to estimate the earliest possible closing date.
- Monitor for any voluntary extensions of the waiting period by the parties.
- Review the company's Form 10-K for the most recent financial position and liquidity status, as this 8-K contains no financial data.
- Assess the potential impact of the transaction delay on DaVita's capital allocation strategy, specifically regarding stock repurchases.